Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Halberd Corp HALB

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and cerebrospinal fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other viruses. Its Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without side effects. The Company’s wholly owned subsidiary is Alaric Corporation.


OTCPK:HALB - Post by User

<< Previous
Bullboard Posts
Next >>
Post by averagepennieson Nov 15, 2023 9:04am
41 Views
Post# 35736438

Halberd Corporation Plans to Extend Research Partnership wit

Halberd Corporation Plans to Extend Research Partnership wit

JACKSON CENTER, PA / ACCESSWIRE / November 15, 2023 / Halberd Corporation (OTC PINK:HALB) is in talks with Mississippi State University (MSU) to extend its original six-month research arrangement by an additional two years, encompassing yet-to-be defined projects. This decision stems from MSU's exceptional performance in the recent TBI Nasal Spray project, as well as the proficiency, capabilities, efficiency, and professionalism exhibited by the MSU team. Notably, the positive interpersonal connections formed between Dr. Russell Carr, the Primary Investigator, and Halberd's scientific leaders have influenced this decision.

Dr. Carr remarked, "The preliminary investigation, spanning six months, confirmed the compelling effectiveness of Halberd's nasal spray in diminishing indicators of imminent brain damage following head trauma. Collaborating with Halberd's scientists has been a gratifying experience, and I am pleased to contribute to the team that validated the efficacy of their groundbreaking nasal spray product."

Mitchell S. Felder, M.D., the Chief Technology Officer at Halberd Corporation, a prolific inventor, and a board-certified attending neurologist, stated, "Our aim is to leverage the extended research collaboration duration at MSU to establish statistically significant findings regarding the efficacy of our patent-pending nasal spray in treating head trauma cases by mitigating the cascade of inflammatory cytokines and neurotransmitters, as well as explore the efficacy of additional products which Halberd has pending."

 

https://www.accesswire.com/803506/halberd-corporation-plans-to-extend-research-partnership-with-mississippi-state-university

<< Previous
Bullboard Posts
Next >>